EP0539547A1 - Procede de preparation de lymphocytes b et t specifiques d'antigenes et anticorps monoclonaux ainsi obtenus - Google Patents
Procede de preparation de lymphocytes b et t specifiques d'antigenes et anticorps monoclonaux ainsi obtenusInfo
- Publication number
- EP0539547A1 EP0539547A1 EP92909718A EP92909718A EP0539547A1 EP 0539547 A1 EP0539547 A1 EP 0539547A1 EP 92909718 A EP92909718 A EP 92909718A EP 92909718 A EP92909718 A EP 92909718A EP 0539547 A1 EP0539547 A1 EP 0539547A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- cells
- lymphocytes
- adherent
- presenting cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 24
- 108091007433 antigens Proteins 0.000 title claims abstract description 24
- 102000036639 antigens Human genes 0.000 title claims abstract description 24
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 10
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 30
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 27
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 23
- 230000001464 adherent effect Effects 0.000 claims abstract description 22
- 210000001124 body fluid Anatomy 0.000 claims abstract description 11
- 239000010839 body fluid Substances 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 210000003567 ascitic fluid Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 210000004880 lymph fluid Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 238000012364 cultivation method Methods 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- -1 llergens Species 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002609 medium Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
Definitions
- the present invention relates to a method for providing antigen-specific B and T lymphocytes, 5 in which body fluids and / or tissues from
- Mammals isolated antigen-presenting cells and lymphocytes are incubated together for a specific adhesion and cultured according to conventional methods.
- the present invention is therefore based on the object of providing a method with which this can be avoided.
- antigen-presenting cells and lymphocytes are isolated from various body fluids and / or tissues from mammals.
- Blood, lymph, pleural, peritoneal and synovial fluid and cerebrospinal fluid are to be mentioned here in particular as body fluids.
- the body fluids can be taken from both healthy and sick mammals. The same applies to
- Tissues of which the spleen, lymph nodes, bone marrow, skin and tumors are to be specified.
- mammals 5 are meant in particular humans, domestic and laboratory animals, whereby domestic animals are also to be understood as domestic animals.
- body fluids and / or tissues can originate from one or more mammals. It is not imperative that, when using several mammals, they all belong to one of the groups mentioned above.
- the method according to the invention is just as limited to
- Mammals rather it includes all living things from the animal kingdom, from which the above cells can be isolated.
- Ficoll-Hypaque centrifugation method can be used to isolate the antigen-presenting cells and the lymphocytes.
- body fluids are used directly, while solid tissues and tumors are centrifuged only after individual preparation by comminution and digestion with conventional enzymes, such as collagenase dispase or trypsin, under conditions such as 1 h at 37 ° C.
- the antigen-presenting cells and the lymphocytes are obtained in the interphase and then washed several times with a physiological buffer, for example PBS, pH 7.2.
- the antigen-presenting cells are separated from the lymphocytes.
- Known methods can be used for this.
- the cells are in one
- Culture vessel incubated with serum-free medium, for example RPMI 1640 or CG medium, under customary conditions, such as 37 ° C. and 5% CO.
- the culture vessel has a coating with plasma or serum, which comes from the same mammal (autologous) or from the same species (allogeneic) from which the antigen-presenting cells and the lymphocytes have been isolated.
- the antigen-presenting cells spontaneously adhere to the coating, whereas the lymphocytes remain in suspension. After an hour's incubation, the lymphocytes are pipetted off, while the antigen-presenting cells remain.
- the lymphocytes are freed from suppressive cells, for which purpose they are treated, for example, with leucine methyl ester (1.25 mM) for 30 minutes at room temperature and then several times in the above-mentioned, serum-free cells
- the antigen-presenting cells are activated, whereby they are treated differently according to their maturity.
- Antigen-presenting cells made of solid tissue are mature in many cases and therefore highly active. In contrast, they are often not mature from body fluids and are therefore incubated for about 24 hours in the culture vessels specified above, e.g. CG medium specified above is used.
- Factors for induction such as interleukin-1, interleukin-6, adenosine or dibutyryl-cAMP, are advantageously added.
- antigen-presenting cells from bone marrow are usually still present as precursor cells and are therefore incubated in one of the media specified above for about 1 week.
- Factors such as linoleic acid (4.ug/ml), vitamin D3 (2.5 M), vitamin E (0.1%), multi-CSF (2 U / ml) and M-CSF (3 U / ml ) added.
- Added antigen is, for example, in the range from 1 ⁇ g to 10 ⁇ g / ml culture medium. It is added from a few minutes to 24 hours.
- Whole or parts of cells, pathogens and / or biomolecules can be mentioned as antigen. Under cells there are both normal and to understand virus-modified and pathologically degenerate.
- the pathogens include viruses, bacteria and allergens, while the biomolecules include antibodies, mediators, enzymes and neurotransmitters.
- the antigens can be used as such alone or in combination with conventional carrier molecules, both of which are also used in mixtures with common adjuvants.
- the antigen-presenting cells and the lymphocytes are incubated together for specific adhesion.
- the cells are introduced into the culture vessels specified above, the lymphocytes being in a 10 to 1000-fold excess, and cultured with one of the media mentioned above.
- the cultivation time is 15 minutes to 2 days at 37 ° C or a maximum of 24 hours at 4 ° C.
- the non-adherent cells are separated from the adherent ones. To do this, wash the coated ones carefully by rinsing them carefully
- the adherent cells are further cultivated by customary methods. They are incubated in the culture vessels specified above.
- As the medium an above-mentioned one is used, to which factors that require proliferation, such as interleukin-2, -4 or -6, can be added.
- a conditioned medium which is obtained, for example, from permanent cell cultures, can also be added.
- the incubation leads to the proliferation of antigen-specific B and T lymphocytes. Unspecific lymphocytes are only formed in an extremely small amount. After 4 days of incubation, antibodies are obtained in the supernatants, the amount of which can be increased by further incubation. It is also advantageous to add fresh medium with proliferation-promoting factors every week. If necessary, antigen-presenting cells can also be added, but these should correspond to the originally used cells.
- the antibodies obtained according to the invention are highly specific against the antigens used, in particular after cloning. It is then a monoclonal idiotype
- Antibodies also anti-idiotype antibodies if an antibody has been used as the antigen.
- the antigen-specific B and T lymphocytes obtained according to the invention are extremely homogeneous in themselves. After cloning, they are particularly suitable for the isolation of specific nucleic acid precursors, for example mRNA, which can then be used for gene cloning purposes and for the amplification of specific nucleic acid sequences using known techniques, for example PCR methods. Furthermore, the B- and T lymphocytes for adoptive immunotherapy. Furthermore, they can also be immortalized by conventional methods, such as fusion with hybridoma cells. The B lymphocytes obtained according to the invention can furthermore be cultured and expanded further by adding anti-CD40 antibodies.
- Ficoll-Hypaque centrifugation method isolated and separated from each other in culture vessels with autologous plasma coating.
- the lymphocytes were freed from suppressive cells by treatment with leucine methyl ester, while the antigen-presenting cells were incubated with 0, 1 and 10 ng tetanus toxoid / ml medium for 24 h as described above. The antigen was then washed out.
- the antigen-presenting cells and the lymphocytes were incubated together with CG medium in the culture vessels described above.
- the lymphocytes were in 200-fold excess. After 24 hours of incubation, the non- adherent cells removed by careful pipetting. Fresh medium supplemented with conditioned medium was added to the adherent cells. After 6 days of incubation, cell count, total antibody amount and specific
- Antibody amount determined.
- the specific antibody synthesis was determined in an ELISA using a tetanus toxoid bound to plastic as the antigen.
- the non-specific antibody synthesis was also determined in an ELISA using a mouse antibody directed against human Ig.
- antigen-specific B and T lymphocytes are preferably provided in the methods according to the invention, whereas non-antigen-specific ones are largely diluted.
Abstract
Selon un procédé de préparation de lymphocytes B et T spécifiques d'antigènes, on isole des fluides et/ou des tissus organiques de mammifères des cellules et des lymphocytes présentant des antigènes, on les incube ensemble afin d'obtenir une adhérence spécifique et on les cultive par un procédé usuel. Ce procédé se caractérise par le fait que l'on sépare les cellules adhérentes des cellules non adhérentes et que l'on ne cultive pas les cellules non adhérentes, mais uniquement les cellules adhérentes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4116078 | 1991-05-16 | ||
DE4116078 | 1991-05-16 | ||
DE4216355A DE4216355A1 (de) | 1991-05-16 | 1992-05-18 | Verfahren zur bereitstellung von antigen-spezifischen b- und t-lymphozyten sowie davon erhaltene monoklonale antikoerper |
DE4216355 | 1992-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0539547A1 true EP0539547A1 (fr) | 1993-05-05 |
Family
ID=25903683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92909718A Withdrawn EP0539547A1 (fr) | 1991-05-16 | 1992-05-18 | Procede de preparation de lymphocytes b et t specifiques d'antigenes et anticorps monoclonaux ainsi obtenus |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0539547A1 (fr) |
JP (1) | JPH06500023A (fr) |
CA (1) | CA2087157A1 (fr) |
DE (1) | DE4216355A1 (fr) |
WO (1) | WO1992020783A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100896540B1 (ko) * | 2000-05-16 | 2009-05-07 | 길 아르노 | 너트 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4422020A1 (de) * | 1993-07-29 | 1995-02-02 | Bernhard Heising | Pharmazeutische Zusammensetzung |
CA2188165C (fr) | 1994-04-28 | 2007-08-28 | Marilyn Kehry | Methode de multiplication et differenciation des cellules b et leur utilisation |
JPH08333262A (ja) * | 1995-04-07 | 1996-12-17 | Chugai Pharmaceut Co Ltd | 免疫抑制剤 |
JP6546219B2 (ja) * | 2017-06-30 | 2019-07-17 | テルモ株式会社 | シート状細胞培養物の製造方法 |
JP7002497B2 (ja) * | 2019-06-20 | 2022-01-20 | テルモ株式会社 | シート状細胞培養物の製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007077A1 (fr) * | 1987-03-11 | 1988-09-22 | The Children's Hospital, Incorporated | Procede de production de lignees de lymphocytes t a specificite antigenique et utilisation therapeutique |
-
1992
- 1992-05-18 JP JP4509204A patent/JPH06500023A/ja active Pending
- 1992-05-18 EP EP92909718A patent/EP0539547A1/fr not_active Withdrawn
- 1992-05-18 WO PCT/EP1992/001089 patent/WO1992020783A1/fr not_active Application Discontinuation
- 1992-05-18 DE DE4216355A patent/DE4216355A1/de not_active Withdrawn
- 1992-05-18 CA CA002087157A patent/CA2087157A1/fr not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9220783A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100896540B1 (ko) * | 2000-05-16 | 2009-05-07 | 길 아르노 | 너트 |
Also Published As
Publication number | Publication date |
---|---|
CA2087157A1 (fr) | 1992-11-17 |
DE4216355A1 (de) | 1992-11-26 |
WO1992020783A1 (fr) | 1992-11-26 |
JPH06500023A (ja) | 1994-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5849589A (en) | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells | |
Inaba et al. | Isolation of dendritic cells | |
DE60218302T2 (de) | Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten | |
RU2202615C2 (ru) | Моноклональное антитело, способное распознавать антиген, вызывающий апоптоз миелоидных клеток костного мозга, и обладающее свойством вызывать апоптоз миеломных клеток, его фрагмент и гибридома | |
KR100223395B1 (ko) | 사람수지상세포의시험관내생성방법및이의용도 | |
DE69839215T2 (de) | Dendritische zellhybride | |
DE60210623T2 (de) | Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen | |
US8603815B2 (en) | CD4+ CD25− T cells and Tr1-like regulatory T cells | |
EP0093436B1 (fr) | Procédé de préparation de lignées de cellules animales et humaines permanentes et leur application | |
US8815543B2 (en) | Methods of producing antigen-specific B cell populations in the presence of CD40:CD40L, BAFF:BAFF receptor and Fas:FasL stimulation | |
CN106282108A (zh) | 一种具有免疫调节功能的脾脏间充质干细胞及其制备方法与应用 | |
CN113293132A (zh) | 一种nk细胞体外扩增体系及培养方法 | |
EP0539547A1 (fr) | Procede de preparation de lymphocytes b et t specifiques d'antigenes et anticorps monoclonaux ainsi obtenus | |
CH683526A5 (de) | Zellinie für die Herstellung von Antikörper bildenden Hybridomen, Verfahren zur Herstellung einer menschlichen Zellinie und Antikörper produzierendes Hybridom. | |
Czarnetzki et al. | Evidence that tissue mast cells derive from mononuclear phagocytes | |
Nozawa et al. | Inhibiton by glucocorticoids and choleragen of the conditional growth of poorly adherent mononuclear phagocytes of newborn hamster liver and lung (Hormonal control of macrophage growth) | |
Geppert et al. | Immobilized anti-CD3-induced T cell growth: comparison of the frequency of responding cells within various T cell subsets | |
Goodell et al. | Canine dendritic cells from peripheral blood and lymph nodes | |
WO2000011139A9 (fr) | Population de cellules contenant des hemangioblastes d'origine non foetale et leur procede de production | |
EP0431125A1 (fr) | Procede de production d'anticorps monoclonaux humains | |
Treves | The origin of monocyte-macrophage heterogeneity: Possible alternative | |
WO2008056734A1 (fr) | Procédé de production de cellules dendritiques à partir de cellules souches d'embryons humains | |
EP2025747A1 (fr) | Procédé d'amplification in vitro de lymphocytes T-régulateurs | |
EP0910624B1 (fr) | Procede de production et de multiplication de lymphocytes | |
KR20170104694A (ko) | 면역 억제 능력을 가지는 수지상세포-유사 세포 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19980618 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990810 |